We are witnessing a long-awaited transformation in depression care. After decades of incremental change, new therapeutic ...
Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...
At its second attempt, Rocket Pharma has won FDA approval for its gene therapy for severe leukocyte adhesion deficiency type ...
Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...
With the ink barely dry on one takeover agreement, Novartis has signed another, promising to pay up to $2 billion to acquire ...
A machine learning (ML) tool that analyses electronic health record data, test results, and patient demographics can help ...
The data reveal from the phase 1 INLIGHT study of WVE-007 – an oligonucleotide-based gene-silencing drug designed to switch ...
Almost four months ahead of schedule, Corcept Therapeutics' selective glucocorticoid receptor antagonist (SGRA) relacorilant ...
Every clinical trial is built on the promise that the risk is justified by the strength of the evidence supporting it.
Denali Therapeutics' Avlayah is the first drug for neurological complications associated with the rare lysosomal storage ...
What is less often examined is how healthcare professionals actually experience survey design, and where common research ...
Novo Nordisk has reported the first mid-stage clinical data with its triple G agonist for diabetes in China, as it starts an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results